IGF1R and osteosarcoma: Finally, the IGF1R binding arm in the tetraspecific antibodies is derived from R1507, which was studied in a Phase II trial in patients with recurrent or refractory osteosarcoma or soft tissue sarcomas (Pappo et al., 2014).